AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Evaluation of QoL, Tolerability and Use of Zoladex 10,8 SafeSystem for Advanced PCa - German IPEP Trial

Completed

Conditions: Prostate Carcinoma

First Posted Date: 2007-10-05

Last Posted Date: 2007-10-05

Lead Sponsor: AstraZeneca

Target Recruit Count: 1950

Registration Number: NCT00540059

Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Paclitaxel
Drug: AZD2171
Drug: Carboplatin

First Posted Date: 2007-10-04

Last Posted Date: 2011-06-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 6

Registration Number: NCT00539331

Locations: 🇯🇵
Research Site, Tokyo, Japan

Phase I Multiple-Ascending Dose (Japan)

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: Dapagliflozin

First Posted Date: 2007-10-02

Last Posted Date: 2015-03-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 36

Registration Number: NCT00538174

Locations: 🇯🇵
Local Institution, Suita, Osaka, Japan

Liver Safety Under Upfront Arimidex vs Tamoxifen

Phase 4

Completed

Conditions: Breast Cancer

Interventions: Drug: Anastrozole
Drug: Tamoxifen

First Posted Date: 2007-10-01

Last Posted Date: 2013-01-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 384

Registration Number: NCT00537771

Locations: 🇨🇳
Research Site, Tianjin, China

Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

Completed

Conditions: Hyperlipidemias
Peripheral Vascular Diseases
Diabetes Mellitus
Atherosclerosis
Coronary Heart Disease
Carotid Stenosis

First Posted Date: 2007-09-28

Last Posted Date: 2014-10-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 951

Registration Number: NCT00536965

Locations: 🇦🇹
Research Site, Vienna, Austria

Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Budesonide/formoterol pMDI 40/2.25ug + spacer
Drug: Budesonide/formoterol pMDI 40/2.25 ug

First Posted Date: 2007-09-28

Last Posted Date: 2012-04-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 107

Registration Number: NCT00536913

Locations: 🇷🇺
Research Site, Moscow, Russian Federation

Symbicort Rapihaler Therapeutic Equivalence Study

Phase 3

Completed

Conditions: Bronchial Asthma

Interventions: Drug: Pulmicort Turbuhaler
Drug: Symbicort pMDI
Drug: Symbicort Turbuhaler

First Posted Date: 2007-09-28

Last Posted Date: 2012-08-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 742

Registration Number: NCT00536731

Locations: 🇵🇱
Research Site, Wroclaw, Poland

Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

Completed

Conditions: Peripheral Vascular Diseases
Atherosclerosis
Hyperlipidemias
Diabetes Mellitus
Coronary Heart Disease
Carotid Stenosis

First Posted Date: 2007-09-28

Last Posted Date: 2014-10-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 1096

Registration Number: NCT00536796

Locations: 🇦🇹
Research Site, Rohrbach, Upper Austria, Austria

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 4

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Gefitinib
Procedure: CT or MRI
Drug: Docetaxel

First Posted Date: 2007-09-27

Last Posted Date: 2013-10-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 14

Registration Number: NCT00536107

Locations: 🇨🇳
Research Site, Taipei, Taiwan

What is the Predictive Value of the Reflux Impact Scale

Terminated

Conditions: Gastroesophageal Reflux Disease
GERD
Heartburn
Acid Regurgitation
Retrosternal Pain

First Posted Date: 2007-09-27

Last Posted Date: 2008-07-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 938

Registration Number: NCT00536328

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy